In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase

Biochemical Pharmacology

Volumn 53, Issue 1, 1997, Pages 67-74

  Bahl, Joseph J ^a,c   Matsuda, Masafumi ^b   Defronzo, Ralph A ^b   Bressler, Rubin ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

gluconeogenic inhibitor; hepatic glucose production; hypoglycemic agents; pyruvate carboxylase

Indexed keywords

ALKANOIC ACID; ASPARTIC ACID; COENZYME A; GLUCOSE; GLUTAMINE; GLYCOGEN; LACTIC ACID; PALMITIC ACID; PHENYLACETIC ACID; PYRUVATE CARBOXYLASE; PYRUVIC ACID; RADIOISOTOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ESTERIFICATION; GLUCONEOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; LIVER MITOCHONDRION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; GLUCOSE; HYPOGLYCEMIC AGENTS; LIVER; MALE; PHENYLPROPIONATES; PYRUVATE CARBOXYLASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031060687     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00660-0     Document Type: Article

References (56)

1. DeFronzo RA, Bonadonna RC and Ferrannini E, Pathogenesis of NIDDM: A balanced overview. Diabetes Care 15: 318-368, 1992.
2. DeFronzo RA, Ferrannini E and Simonson DC, Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38: 387-395, 1989.
3. 3H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used. J Clin Invest 78: 1479-1486, 1986.
4. DeFronzo RA, The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.
5. DeFronzo RA and Ferrannini E, Regulation of hepatic glucose metabolism in humans. Diabetes Metab Rev 3: 415-459, 1987.
6. Consoli A, Nurjhan N, Capani F and Gerich J, Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38: 550-557, 1989.
7. Rossetti L, Giaccari A, Barzilai N, Howard K, Sebel G and Meizhu H, Mechanisms by which hyperglycemia inhibits hepatic glucose production in conscious rats. J Clin Invest 92: 1126-1134, 1993.
8. Ferrannini E, Simonson DC, Katz LD, Reichard G Jr, Bevilacqua S, Barrett EJ, Olsson M and DeFronzo RA, The disposal of an oral glucose load in patients with non-insulindependent diabetes. Metabolism 37: 79-85, 1988.
9. DeFronzo RA, Tobin JD and Andres R, Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Pkysiol 237: E214-E223, 1979.
10. Consoli A, Kennedy F, Miles J and Gerich J, Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man. J Clin Invest 80: 1303-1310, 1987.
11. Mitrakou A, Kelley D, Veneman T, Jensen T, Pangburn T, Reilly J and Gerich J, Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39: 1381-1390, 1990.
12. 13C nuclear magnetic resonance study. J Clin Invest 90: 1323-1327, 1992.
13. Consoli A, Nurjhan N, Reilly JJ Jr, Bier DM and Gerich JE, Mechanism of increased gluconeogenesis in noninsulindependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Invest 86: 2038-2045, 1990.
14. Ferrannini E and Groop LC, Hepatic glucose production in insulin-resistant states. Diabetes Metab Rev 5: 711-726, 1989.
15. Attwood PA and Keech DB, Pyruvate carboxylase. Curr Top Cell Regul 23: 1-55, 1984.
16. Walter P, Pyruvate carboxylase: Intracellular localization and regulation. In: Gluconeogenesis: Its Regulation in Mammalian Species (Eds. Hanson RW and Mehlman MA), pp. 239-265. John Wiley, New York, 1976.
17. Utter MF, Barden RE and Taylor BL, Pyruvate carboxylase: An evaluation of the relationships between structure and mechanism and between structure and catalytic activity. Adv Enzymol 42: 1-72, 1975.
18. Granner D and Pilkis S, The genes of hepatic glucose metabolism. J Biol Chem 265: 10173-10176, 1990.
19. Bressler R and Bahl JJ, Insulin regulation of metabolism relevant to gluconeogenesis. In: Handbook of Experimental Pharmacology (Eds. Cuatrecasas P and Jacobs SJ), pp. 451-467. Springer, New York, 1989.
20. Hue L, Gluconeogenesis and its regulation. Diabetes Metab Rev 3: 111-126, 1987.
21. González de Galdeano L, Bressler R and Brendel K, Inhibition of gluconeogenesis in the isolated perfused rat liver by ω-phenylalkanoic acids. J Biol Chem 248: 2514-2520, 1973.
22. McQueen CA and Williams GM, The use of cells from rat, mouse, hamster and rabbit in the hepatocyte primary culture/ DNA-repair test. Ann NY Acad Sci 407: 119-130, 1983.
23. 2 production from several small reaction mixtures. Anal Biochem 60: 88-101, 1974.
24. Sordahl LA, Johnson C, Blailock ZR and Schwartz A, The mitochondrion. In: Methods in Pharmacology (Ed. Schwartz A), pp. 247-286. Meredith Corporation, New York, 1971.
25. Corkey BE, Brandt M, Williams RJ and Williamson JR, Assay of short-cham acyl coenzyme A intermediates in tissue extracts by high-pressure liquid chromatography. Anal Biochem 118: 30-41, 1981.
26. 2-terminal and biotin peptide. Arch Biochem Biophys 266: 270-276, 1988.
27. Scrutton MC, Olmsted MR and Utter MF, Pyruvate carboxylase from chicken livers. Methods Enzymol 13: 235-249, 1969.
28. Trinder P, Determination of glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen. J Clin Patho 22: 158-161, 1969.
29. Exton JH and Park CR, Control of gluconeogenesis in liver. J Biol Chem 242: 2622-2636, 1967.
30. Kraegen EW, James DE, Bennett SP and Chisholm DJ, In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am J Physiol 245: E1-E7, 1983.
31. Rossetti L, Smith D, Shulman GI, Papachristou D and DeFronzo RA, Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510-1515, 1987.
32. Rossetti L, Normalization of insulin sensitivity with lithium in diabetic rats. Diabetes 38: 648-652, 1989.
33. Rossetti L and Laughlin MR, Correction of chronic hyperglycemia with vanadate, but not phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84: 892-899, 1989.
34. Somogyi M, Determination of blood sugar. J Biol Chem 160: 69-73, 1945.
35. Morgan CR and Lazarow A, Immunoassay of insulin: Two antibody system. Plasma insulin levels of normal, subdiabetic and diabetic rats. Diabetes 12: 115-126, 1963.
36. Rossetti L and Giaccari A, Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose-uptake: A dose-response euglycemic clamp study in normal and diabetic rats. J Clin Invest 85: 1785-1792, 1990.
37. Steele R, Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420-430, 1959.
38. Williamson JR, Browning ET and Olson MS, Interrelationships between fatty acid oxidation and the control of gluconeogenesis in perfused rat liver. Adv Enzyme Regul 6: 67-100, 1968.
39. Felig P and Bergman M, Gluconeogenesis. In: Endocrinology and Metabolism (Eds. Felig P, Baxter J and Frohman L), 3rd Edn, pp. 1113-1115. McGraw-Hill, New York, 1995.
40. Chipkin SR, Kelly KL and Ruderman NB, Hormonal-fuel interrelationships: Fed state, starvation, and diabetes mellitus. In: Joslin's Diabetes Mellitus (Eds. Kahn CR and Weir GC), 13th Edn, pp. 97-115. Lea & Febiger, Malvern, PA, 1994.
41. Matsuda M, Consoli A, Bressler P, DeFronzo RA and DelPrato S, Sustained response of hepatic glucose production to glucagon in type 2 diabetic subjects. Diabetologia 35 (Suppl 1): A37, 1992.
42. Barritt GJ, Zander GL and Utter MF, The regulation of pyruvate carboxylase activity and gluconeogenic tissues. In: Gluconeogenesis: Its Regulation in Mammalian Species (Eds. Hanson RW and Mehlman MA), pp. 3-46. John Wiley, New York, 1976.
43. Bressler R, Fatty acid oxidation in lipid metabolism. In: Comprehensive Biochemistry (Eds. Florkin M and Stotz EH), Vol. 18, pp. 331-359. Elsevier, Amsterdam, 1970.
44. Fanelli C, Calderone S, Epifano L, DeVincenzo A, Modarelli F, Pampanelli S, Perriello G, De Feo P, Brunetti P, Gerich JE and Bolli GB, Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. J Clin Invest 92: 1617-1622, 1993.
45. Tutwiler GF and Dellevigne P, Action of the oral hypoglycemie agent 2-tetradecylglycidic acid on hepatic fatty acid oxidation and gluconeogenesis. J Biol Chem 254: 2935-2941, 1979.
46. Tutwiler GF, Mohrbacher R and Ho W, Methyl 2-tetradecylglycidate, an orally effective hypoglycemic agent that inhibits long chain fatty acid oxidation selectively. Diabetes 28: 242-248, 1979.
47. Tutwiler GF, Kirsch T, Mohrbacher R and Ho W, Pharmacologic profile of methyl 2-tetradecylglycidate (McN-3716)an orally effective hypoglycemic agent. Metabolism 27: 1539-1556, 1978.
48. Lardy HA, Paetkau V and Walter P, Paths of carbon in gluconeogenesis and lipogenesis: The role of mitochondria in supplying precursors of phosphoenolpyruvate. Proc Natl Acad Sci USA 53: 1410-1415, 1965.
49. Haeckel R, Oellerich M and Binder L, Hydrazopropionic acid derivatives. In: New Antidiabetic Drugs (Eds. Bailey CJ and Flatt PR), pp. 206-216. Smith Gorman Co., London, 1990.
50. Wolf HPO, Aryl-substituted 2-oxirane carboxylic acids: A new class of antidiabetic drugs. In: New Antidiabetic Drugs (Eds. Bailey CJ and Flatt PR), pp. 217-229. Smith Gorman Co., London, 1990.
51. Rossetti L, DeFronzo RA, Gherzl R, Stern P, Andraghetti G, Falzetti G, Shulman GI, Klein-Robbenhaar E and Cordera R, Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations. Metabolism 39: 425-435, 1990.
52. Simell O, Sipilä I, Rajantie J, Valle DL and Brusilow SW, Waste nitrogen excretion via amino acid acylation: Benzoate and phenylacetate in lysinuric protein intolerance. Pediatr Res 20: 1117-1121, 1986.
53. Samid D, Ram Z, Hodgins WR, Shack S, Liu L, Walbridge S, Oldfield EH and Meyers CE, Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891-895, 1994.
54. Samid D, Shack S and Sherman LT, Phenylacetate: A novel nontoxic inducer of tumor cell differentiation. Cancer Res 52: 1988-1992, 1992.
55. Samid D, Yeh A and Prasanna P, Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80: 1576-1581, 1992.
56. Samid D, Shack S and Meyers CE, Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295, 1993.